热血素通过RhoA/ROCK通路刺激人体内皮内氨酶酶活性:对动脉样硬化内皮功能障碍的影响
Xiu-Fen Ming1, Christine Barandier, Hema Viswambharan
1Vascular Biology, Department of Medicine, Division of Physiology, University of Fribourg, Fribourg, Switzerland.
Circulation
|December 1, 2004
概括
热血素通过RhoA/ROCK在内皮细胞中增加阿尔金纳酶活性. 这种高活性有助于动脉样硬化中的内皮功能障碍,这表明阿尔金酶是治疗点.
科学领域:
- 血管生物学 血管生物学
- 生物化学 生物化学
- 心血管研究研究心血管研究
背景情况:
- 阿基因酶与内皮氧化合成酶 (eNOS) 竞争L-阿基因,减少氧化 (NO) 的产生.
- 了解氨酶调节对于解决内皮功能障碍和动脉样硬化至关重要.
研究的目的:
- 调查内皮细胞中阿基纳酶活性的调节机制.
- 确定阿尔金纳在动脉样硬化的发病过程中的作用.
主要方法:
- 评估了由血栓激素刺激的人类静脉内皮细胞中的阿基纳酶活性.
- 利用RhoA/ROCK通路抑制剂和激活剂来研究信号传递.
- 在动脉样硬化的apoE-/-小鼠的大动脉中分析了酶II和RhoA水平.
- 在小鼠模型中检查了对L-氨酸和氨酶抑制的血管反应.
主要成果:
- 通过RhoA/ROCK通路,血栓素剂量和时间的依赖性增加了阿基纳酶活性.
- 活跃的RhoA和ROCK突变物显著增强了阿根酶活性.
- 在动脉样硬化小鼠的大动脉中观察到较高的酶II活性和RhoA水平.
- 在动脉样硬化小鼠中,阿基纳酶抑制改善了血管扩张.
结论:
- 血栓激素通过RhoA/ROCK通路刺激内皮质阿尔基纳酶活性.
- 氨酶活性增加有助于动脉样硬化中的内皮功能障碍.
- 针对血管阿尔金纳是一种潜在的动脉样硬化治疗策略.
相关概念视频
Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Intracellular Signaling Affects Focal Adhesions
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...


